Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments.

ABSTRACT:

Introduction

Identifying low-cost, minimally-invasive screening instruments for Alzheimer's disease (AD) trial enrichment will improve the efficiency of AD trials.

Methods

A total of 685 cognitively normal (CN) individuals and individuals with mild cognitive impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were grouped according to cutoffs of genetic risk factor (G) polygenic hazard score (PHS) and tau pathology (T) plasma phosphorylated tau-181 (p-tau181) into four groups: G+T+, G-T-, G+T-, and G-T+. We assessed the associations between group level and longitudinal cognitive decline and AD conversion. Power analyses compared the estimated sample size required to detect differences in cognitive decline.

Results

The G+T+ group was associated

SUBMITTER: Wang X 

PROVIDER: S-EPMC11667492 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature